AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33256777 — intervention group
Group type: COMPARATOR
Intervention: Infants born weighing 1500-2499 g
Number of subjects: 0
Study 33256777 — intervention group
Group type: COMPARATOR
Intervention: Infants born preterm (< 37 weeks)
Number of subjects: 0
Study 33256777 — intervention group
Group type: COMPARATOR
Intervention: One-week decrease in gestational age at delivery
Number of subjects: 0
Study 33256777 — intervention group
Group type: COMPARATOR
Intervention: Bag/mask ventilation
Number of subjects: 0
Study 33256777 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 0
Study 33256777 — intervention group
Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 0
Study 33256782 — intervention group
Group type: EXPERIMENTAL
Intervention: Babies born weighing ≥ 2500 g
Number of subjects: 0
Study 33256782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pakistan site
Number of subjects: 0
Study 33256782 — intervention group
Group type: EXPERIMENTAL
Intervention: Zambian/Kenyan sites
Number of subjects: 0
Study 33256782 — intervention group
Group type: EXPERIMENTAL
Intervention: Zambia/Kenya and India
Number of subjects: 0
Study 33256782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pakistan and Guatemala
Number of subjects: 0
Study 33256782 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal factors
Number of subjects: 0
Study 33256782 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal characteristics
Number of subjects: 0
Study 33256782 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 0
Study 33256783 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based study across 7 sites in LMIC
Number of subjects: 573148
Study 33256783 — intervention group
Group type: COMPARATOR
Intervention: Guatemala site
Number of subjects: 573148
Study 33256783 — intervention group
Group type: COMPARATOR
Intervention: African sites
Number of subjects: 573148
Study 33256783 — intervention group
Group type: COMPARATOR
Intervention: Asian sites
Number of subjects: 573148
Study 33256783 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with less education and access to antenatal care
Number of subjects: 573148
Study 33256783 — intervention group
Group type: EXPERIMENTAL
Intervention: Major fetal causes of stillbirth
Number of subjects: 573148
Study 33256783 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal conditions observed
Number of subjects: 573148
Study 33256784 — intervention group
Group type: EXPERIMENTAL
Intervention: Short IDI (6-17 months)
Number of subjects: 181782
Study 33256784 — intervention group
Group type: EXPERIMENTAL
Intervention: IDI of 37-60 months
Number of subjects: 181782
Study 33256784 — intervention group
Group type: EXPERIMENTAL
Intervention: Long IDI (61-180 months)
Number of subjects: 181782
Study 33256784 — intervention group
Group type: EXPERIMENTAL
Intervention: Short and long IDIs
Number of subjects: 181782
Study 33256784 — intervention group
Group type: COMPARATOR
Intervention: Reference IDI (18-36 months)
Number of subjects: 181782
Study 33256790 — intervention group
Group type: EXPERIMENTAL
Intervention: Care around Delivery (CAD) - 8 practices recommended as part of the Essential Newborn Care (ENC) package
Number of subjects: 150848
Study 33256790 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery by skilled birth attendant, presence of fetal heart, delayed bathing
Number of subjects: 150848
Study 33256790 — intervention group
Group type: EXPERIMENTAL
Intervention: Present indicators (8 practices) of CAD
Number of subjects: 150848
Study 33256829 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg IV on cycle 1 day 1 and carboplatin IV AUC=5 on cycle 1 day 8; trastuzumab for HER2-positive patients
Number of subjects: 38
Study 33256829 — intervention group
Group type: COMPARATOR
Intervention: ECOG PS 1-2
Number of subjects: 38
Study 33256890 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG seroconversion
Number of subjects: 177
Study 33256890 — intervention group
Group type: EXPERIMENTAL
Intervention: Serologic assays
Number of subjects: 177
Study 33257140 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosomal microRNAs (mir-483-5p and mir-126-3p) from bile samples
Number of subjects: 82
Study 33257140 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosomal microRNAs (mir-483-5p and mir-126-3p)
Number of subjects: 82
Study 33257140 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonmalignant biliary obstruction)
Number of subjects: 82
Study 33257189 — intervention group
Group type: EXPERIMENTAL
Intervention: High myocardial oxygen demand
Number of subjects: 106
Study 33257488 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with neurological manifestations
Number of subjects: 1342
Study 33257488 — intervention group
Group type: COMPARATOR
Intervention: Patients without neurological manifestations
Number of subjects: 1342
Study 33257493 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing leaders' approach and experiences in lung choirs
Number of subjects: 20
Study 33257493 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing leaders' experiences
Number of subjects: 20
Study 33257972 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable cardioverter-defibrillator (WCD)
Number of subjects: 1157
Study 33257977 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy with fluoropyrimidine, oxaliplatin, and bevacizumab
Number of subjects: 151
Study 33258025 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 45
Study 33258025 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese participants without diabetes
Number of subjects: 45
Study 33258025 — intervention group
Group type: COMPARATOR
Intervention: Lean individuals
Number of subjects: 45
Study 33258025 — intervention group
Group type: COMPARATOR
Intervention: Endurance-trained athletes
Number of subjects: 45
Study 33258331 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) implantation
Number of subjects: 485
Study 33258331 — intervention group
Group type: COMPARATOR
Intervention: Matched control patients (no ICD)
Number of subjects: 485
Study 33258568 — intervention group
Group type: EXPERIMENTAL
Intervention: UCOPD
Number of subjects: 65
Study 33258568 — intervention group
Group type: COMPARATOR
Intervention: no-COPD
Number of subjects: 65
Study 33258687 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite grading algorithm for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Number of subjects: 0
Study 33258687 — intervention group
Group type: COMPARATOR
Intervention: Individual item scores
Number of subjects: 0
Study 33258745 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 28
Study 33258745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 28
Study 33258792 — intervention group
Group type: EXPERIMENTAL
Intervention: mobile-assisted cognitive behavioral therapy for negative symptoms (mCBTn)
Number of subjects: 31
Study 33258793 — intervention group
Group type: EXPERIMENTAL
Intervention: UPrEPU app for adherence monitoring
Number of subjects: 70
Study 33258950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 26
Study 33258950 — intervention group
Group type: COMPARATOR
Intervention: CF Control
Number of subjects: 26
Study 33258996 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic lockdown
Number of subjects: 1964
Study 33259032 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoint inhibition therapy using monoclonal antibodies against PD-1 or PD-L1
Number of subjects: 0
Study 33259326 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support group intervention facilitated by PSWs (10 weekly 90-minute online workshops)
Number of subjects: 20
Study 33259326 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support group intervention facilitated by PSWs
Number of subjects: 20
Study 33259326 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 20
Study 33259448 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand TOF
Number of subjects: 20
Study 33259448 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot TOF
Number of subjects: 20
Study 33259448 — intervention group
Group type: EXPERIMENTAL
Intervention: MMEPs
Number of subjects: 20
Study 33259448 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of Hand TOF and MMEP
Number of subjects: 20
Study 33259460 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent SCS-VR
Number of subjects: 15
Study 33259460 — intervention group
Group type: COMPARATOR
Intervention: Incongruent SCS-VR
Number of subjects: 15
Study 33259460 — intervention group
Group type: COMPARATOR
Intervention: VR alone
Number of subjects: 15
Study 33259484 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart bracelet monitoring
Number of subjects: 100
Study 33259589 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbralisib (800 mg/d)
Number of subjects: 51
Study 33259596 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruton tyrosine kinase inhibitors (BTKi's)
Number of subjects: 2
Study 33259596 — intervention group
Group type: COMPARATOR
Intervention: Treatment naïve (TN)
Number of subjects: 2
Study 33259782 — intervention group
Group type: EXPERIMENTAL
Intervention: TDS (120 µg/day levonorgestrel and 30 µg/day ethinyl estradiol)
Number of subjects: 2032
Study 33259782 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable (single-arm study)
Number of subjects: 2032
Study 33259845 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM)
Number of subjects: 67
Study 33259845 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (T1DM)
Number of subjects: 67
Study 33259921 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicutaneous immunotherapy for peanut allergy
Number of subjects: 0
Study 33259921 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33259932 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of androgen deprivation therapy (ADT) concurrent with abiraterone acetate plus prednisone (AAP) once daily and radiation therapy (RT) to prostate and seminal vesicles
Number of subjects: 37
Study 33259932 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of ADT concurrent with AAP and RT
Number of subjects: 37
Study 33260072 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cortical brain infarcts
Number of subjects: 413
Study 33260072 — intervention group
Group type: EXPERIMENTAL
Intervention: More complex shape of white matter hyperintensities
Number of subjects: 413
Study 33260072 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative brain volumes, white matter hyperintensity volume, and cerebral perfusion
Number of subjects: 413
Study 33261573 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundus fluorescein angiography (FFA)
Number of subjects: 324
Study 33261573 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined examination of posterior pole, nasal, and inferior nasal fields
Number of subjects: 324
Study 33261718 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 exposure (index patients)
Number of subjects: 11
Study 33261718 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2 exposure (contacts)
Number of subjects: 11
Study 33261718 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2 exposure (couples and controls)
Number of subjects: 11
Study 33261814 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated plaque characterization (SAPC) analysis via coronary computed tomographic angiography (CTA)
Number of subjects: 259
Study 33262134 — intervention group
Group type: EXPERIMENTAL
Intervention: HPN536 (doses ranging from 0.1 to 10 mg/kg)
Number of subjects: 0
Study 33262134 — intervention group
Group type: EXPERIMENTAL
Intervention: HPN536
Number of subjects: 0
Study 33262580 — intervention group
Group type: EXPERIMENTAL
Intervention: COACHMAN intervention (n = 30)
Number of subjects: 60
Study 33262580 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (n = 30)
Number of subjects: 60
Study 33262641 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolperisone 50 mg TID
Number of subjects: 415
Study 33262641 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolperisone 100 mg TID
Number of subjects: 415
Study 33262641 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolperisone 150 mg TID
Number of subjects: 415
Study 33262641 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolperisone 200 mg TID
Number of subjects: 415
Study 33262641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 33262925 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD.Pal® app (self-management app for COPD)
Number of subjects: 11
Study 33263026 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of sarcoid-like granulomas
Number of subjects: 133
Study 33263037 — intervention group
Group type: EXPERIMENTAL
Intervention: gefapixant 15 mg
Number of subjects: 2044
Study 33263037 — intervention group
Group type: EXPERIMENTAL
Intervention: gefapixant 45 mg
Number of subjects: 2044
Study 33263037 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2044
Study 33263165 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab biosimilars (FKB327, ABP 501, BI 695501, GP2017, MSB11022, PF-06410293, SB5)
Number of subjects: 7
Study 33263165 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching between a biosimilar and the adalimumab RP
Number of subjects: 7
Study 33263318 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC tracking for lung SABR
Number of subjects: 17
Study 33263499 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean-and-Release test
Number of subjects: 26
Study 33263626 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight Digital Monitoring (ODM) using a wireless high-resolution oximeter
Number of subjects: 304
Study 33263626 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 304
Study 33263893 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0
Study 33263893 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC) alone
Number of subjects: 0
Study 33264119 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine administered during anesthesia (μg·kg-1 30 min-1)
Number of subjects: 200
Study 33264119 — intervention group
Group type: EXPERIMENTAL
Intervention: E/e' ratio during anesthesia
Number of subjects: 200
Study 33264183 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tumor necrosis factor therapy
Number of subjects: 30
Study 33264183 — intervention group
Group type: EXPERIMENTAL
Intervention: No activity limitations at diagnosis
Number of subjects: 30
Study 33264183 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 30
Study 33264327 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated preoperative liver cT1 (indicative of fibroinflammation)
Number of subjects: 143
Study 33264327 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score combining FLR and cT1
Number of subjects: 143
Study 33264515 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Number of subjects: 0
Study 33264515 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33267723 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth appointments
Number of subjects: 587
Study 33267723 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medications
Number of subjects: 587
Study 33267723 — intervention group
Group type: EXPERIMENTAL
Intervention: General experiences during COVID-19
Number of subjects: 587
Study 33267723 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to return to primary care clinic
Number of subjects: 587
Study 33267723 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with health guidelines
Number of subjects: 587
Study 33267723 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to healthcare
Number of subjects: 587
Study 33267793 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM group
Number of subjects: 69
Study 33267793 — intervention group
Group type: EXPERIMENTAL
Intervention: M group
Number of subjects: 69
Study 33267793 — intervention group
Group type: COMPARATOR
Intervention: C group
Number of subjects: 69
Study 33267904 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance directives (ADs)
Number of subjects: 8
Study 33267904 — intervention group
Group type: COMPARATOR
Intervention: No advance directives (without ADs)
Number of subjects: 8
Study 33267919 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 97
Study 33267919 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavior therapy (CBT-E)
Number of subjects: 97
Study 33267959 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin delta coadministered with HP-hMG (dosage adjustments confined to HP-hMG only)
Number of subjects: 110
Study 33267959 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin delta coadministered with HP-hMG
Number of subjects: 110
Study 33267959 — intervention group
Group type: COMPARATOR
Intervention: Follitropin delta from ESTHER-1 trial
Number of subjects: 110
Study 33268029 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical natural killer (NK) cell infusions after autologous stem cell transplant (ASCT)
Number of subjects: 10
Study 33268029 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical natural killer (NK) cell infusions
Number of subjects: 10
Study 33268421 — intervention group
Group type: EXPERIMENTAL
Intervention: PharMoG team intervention (clinical medication review)
Number of subjects: 0
Study 33268442 — intervention group
Group type: EXPERIMENTAL
Intervention: iRMD-COVID-19 patients hospitalized
Number of subjects: 694
Study 33268442 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids use in iRMD patients
Number of subjects: 694
Study 33268442 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil use in iRMD patients
Number of subjects: 694
Study 33268442 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab use in iRMD patients
Number of subjects: 694
Study 33268442 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 694
Study 33268442 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 694
Study 33268442 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 694
Study 33268442 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 694
Study 33269010 — intervention group
Group type: EXPERIMENTAL
Intervention: Moroctocog alfa (AF-CC) on-demand treatment
Number of subjects: 138
Study 33269506 — intervention group
Group type: EXPERIMENTAL
Intervention: MeRes100 sirolimus-eluting bioresorbable vascular scaffold (BRS)
Number of subjects: 64
Study 33269549 — intervention group
Group type: EXPERIMENTAL
Intervention: LENT index (combination of LE index and NT-proBNP levels)
Number of subjects: 772
Study 33269549 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission NT-proBNP levels
Number of subjects: 772
Study 33269549 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge NT-proBNP levels
Number of subjects: 772
Study 33269625 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin add-on therapy
Number of subjects: 3372
Study 33270028 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious video game (Land of Secret Gardens)
Number of subjects: 55
Study 33270028 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no game)
Number of subjects: 55
Study 33270130 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 2256
Study 33270130 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic gastric banding (LAGB)
Number of subjects: 2256
Study 33270471 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet aggregation by light transmittance aggregometry; circulating levels of soluble CD40 ligand (sCD40L) measured at three time points (T1, T2, T3).
Number of subjects: 54
Study 33270471 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 patients with negative SARS-CoV-2); same clinical presentation.
Number of subjects: 54
Study 33270528 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 33270816 — intervention group
Group type: EXPERIMENTAL
Intervention: leukemia-specific T cells (mLSTs) administered at escalating doses (0.5 to 10 × 10^7 cells per square meter)
Number of subjects: 25
Study 33270816 — intervention group
Group type: EXPERIMENTAL
Intervention: leukemia-specific T cells (mLSTs)
Number of subjects: 25
Study 33270832 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab discontinuation
Number of subjects: 55
Study 33270832 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 55
Study 33270906 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 5240
Study 33270906 — intervention group
Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 5240
Study 33271094 — intervention group
Group type: EXPERIMENTAL
Intervention: GX-188E therapeutic DNA vaccine plus pembrolizumab
Number of subjects: 36
Study 33272030 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable nitinol stents
Number of subjects: 379
Study 33272031 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolut PRO or Evolut PRO+ transcatheter heart valves (THVs)
Number of subjects: 81
Study 33272037 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 2587
Study 33272037 — intervention group
Group type: COMPARATOR
Intervention: No RBC transfusion
Number of subjects: 2587
Study 33272131 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05230907 at 30 μg/kg
Number of subjects: 21
Study 33272131 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05230907 at doses ranging from 5 to 30 μg/kg
Number of subjects: 21
Study 33272131 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05230907
Number of subjects: 21
Study 33272133 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysmal subarachnoid hemorrhage (aSAH) patients
Number of subjects: 1787
Study 33272236 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretched position
Number of subjects: 20
Study 33272236 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxed position
Number of subjects: 20
Study 33272295 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL from diabetic patients with CAD
Number of subjects: 148